Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI) Read more about Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)
Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation Read more about Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma Read more about Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy Read more about Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study Read more about Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study
Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial. Read more about Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial.
Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort Read more about Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort
Evaluation of a tumor informed MRD assay with contrived breast cancer samples Read more about Evaluation of a tumor informed MRD assay with contrived breast cancer samples
ctDNA dynamics in early stage node negative non-small cell lung cancers Read more about ctDNA dynamics in early stage node negative non-small cell lung cancers